PSA AND PAP CONCENTRATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA BEFORE AND YEAR AFTER ADENOMECTOMY Article published in Urologia Polska 1995/48/1.
authors
-
Jan Kulpa, Andrzej Bugajski 1, Ewa Wójcik, Katarzyna Miodońska 1, Urszula Rychlik
- Z Zakładu Analityki i Biochemii Klinicznej Centrum Onkologii Instytutu im. M. Sklodowskiej-Curie, Oddział w Krakowie
Kierownik Zakładu: Dr n. chem. J. Kulpa
Dyrektor Centrum Onkologii, Oddział w Krakowie: Prof. dr hab. J. Skołyszewski
1 Z Kliniki Urologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie
Kierownik Kliniki Urologii: Doc. dr hab. A. Bugajski
summary
- PSA and PAP concentration were determined in 63 patients with benign prostatic
- hyperplasia before and 12 months after adenomectomy. Prior to surgery, increased PSA
- concentration was found in 87,3% and increased PAP in 11,1% of patients. Twelve months
- after surgery the PSA concentration was significantly lower, compared to the preoperative value
- p<0,0001
- drop after surgery was considerably smaller, only 2 patients after adenomectomy showed the
- marker concentration sligthly exceeding the cut-off value.
- Significant correlation was found between the preoperative concentration of both markers
- and the enucleated adenoma weight.
references
- 1. Althoff E.P., Proppe K.H., Chapman C.M., Lee CH., Prot G.R.: Evaluation of prostate
- acid phosphatase and prostate specific antigen in identification of prostate cancer. J. Urol., 1983,
- 129, 315. ? 2. Armbruster D.A.: Prostate-specific antigen: Biochemistry, analytical methods,
- and clinical application, Clin. Chem., 1993, 39, 181. ? 3. Armitage T.G., Cooper E.H., Newling
- D.W.W., Robinson M.R.G., Appleyard /.: The value of the measurement of serum prostate
- specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br.
- J. Urol., 1988, 62, 584. ? 4. Becker D.H.: Elevated serum prostate specific antigen (PSA) in
- benign prostatic hyperplasia: A retrospective study on 45 patients. W R. Klapdor (ed.) Tumor
- Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the
- Beginning of the Nineties. 1992, W. Zuckschwerdt Verlag, Munchen, Bern Wien, New York,
- str. 153. ? 5. Bilhartz D.L., Tindali D.J., Oesterling J.E.: Prostate-specific antigen and prostatic
- acid phosphatase: Biomolecular and Physiologic characteristics. Urology, 1991, 38, 95. ?
- 6. Brawer M.K., Lange H.P.: Prostate-specific antigen: Its role in early detection, staging, and
- monitoring of prostate carcinoma. J. Endourology, 1989, 3, 227. ? 7. elernents R., Penney
- M.D., Etherington R.J., Griffiths G.J., Hughes H., Peeling W.B.: Volume of normal prostatre, of
- prostate cancer, and of benign prostatic hyperplasia: Are correlations with prostate specific
- antigen Clinically useful? Prostate, 1992, 4 Suppl., 51. ? 8. Collins G.N., Lee R.J., McKelme
- G.B., Rogers A.C.N., Hehir H.: Relationship between prostate specific antigen, prostate volume
- and age in the benign prostate. Br. J. Urol., 1993, 71, 445. ? 9. Kulpa J., Bugajski A., Wójcik
- E., Jaszczyński J.\ Objętość gruczołu a stężenie PAP i PSA u chorych na gruczolak stercza.
- Urol. Pol., 1994, 47, 99. ? 10. Kulpa J., Leńko J., Kwinta A., Wójcik E., Marczyńska A.:
- Kształtowanie się stężenia kwaśnej fosfatazy sterczowej w osoczu krwi u chorych operowanych
- z powodu gruczolaka stercza. Urol. Pol., 1986, 39, 93.
- 11. Oesterling J.E.: Prostate specific antigen: A critical assessment of the most useful tumor
- marker for adenocarcinoma of the prostate. J. Urol., 1991. 145,907. ? 12. Oesterling J.E., Chan
- D.W., Epstein J.I., Kimball A.M., Bruzek D.J., Rock R.C., Brendler Ch.B.: Prostate specific
- antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated
- with radical prostatectomy. J. Urol., 1988, 139, 766. ? 13. Partin A.W., Carter H.B., Chan
- W.D., Epstein JJ., Oesterling J.E., Rock R.C., Weber J.P., Walsh P.C: Prostate specific antigen
- in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and
- benign hyperplasia. J. Urol., 1990. 143, 747. ? 14. Rainwater L.M., Morgan W.R., Klee G.G.,
- Zincke H.\ Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.
- Mayo Clin. Proc, 1990, 65, 1118. ? 15. Ruckle H.C., Klee G.G., Oesterling J.E.: Prostate-
- -specific antigen: Critical issues for the practicing physician. Mayo Clin. Proc, 1994, 69, 59.
- ? 16. Sershon P.D., Barry M.J., Oesterling J.E.: Serum Prostate-specific antigen discriminates
- weakly between men with benign prostatic hyperplasia and patients with organ-confined
- prostate cancer. Eur. Urol., 1994, 25, 282. ? 17. Stamey T.A., Yang N., Hay A.R., McNeal
- J.E., Frehia F.S., Redwine E.: Prostate-specific antigen as a serum marker for adenocarcinoma
- of the prostate. N. Engl. J. Med., 1987, 317, 909. ? 18. Wang M.C, Valenzuela L.A., Murphy
- G.P., Chu T.M.: Purification of human prostate specific antigen. Invest. Urol., 1979,17, 159. ?
- 19. Wolf J.M., Scholz A., Boeckmann W., Jakse G.: Differentiation of benign prostatic
- hyperplasia and prostate cancer empoying Prostatic-specific antigen density. Eur. Urol., 1994,
- 25, 295.
|